Nivolumab,vusolimogene
BMS,Replimune
['rp1', 'ignyte', 'melanoma', 'nivo', '$repl']
2. $repl, 19% (1.6x avg. vol), new data at #asco2023 for ignyte trial of rp1 + nivo in melanoma patients that failed anti-pd1, orr 37.3% in 75 patients, data for all 141 patients exp. in q4 23. $1.3bil. mcap, $583mil. in cash funds into 2h 25, med. price target $52.11 (+130%) 
Biotech stock analyst. Editor of Biotech Millionaire at Mauldin Economics. Tweets and opinions are not investment advice.